Results 61 to 70 of about 989 (143)

Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK‐air and EAACI Methodological Committee Report

Allergy, Volume 80, Issue 12, Page 3319-3330, December 2025.
This study compares different medications for allergic rhinitis on patients' satisfaction and co‐medication use frequency. mHealth data suggest that intranasal corticosteroids (INCS) and fixed combinations of intranasal antihistamines (INAH) and corticosteroids are associated with higher treatment satisfaction than oral antihistamines (OAH).
Bernardo Sousa‐Pinto, Rafael José Vieira, Antonio Bognanni, Matteo Martini, Michal Ordak, Giovanni Paoletti, Sara Gil‐Mata, Rita Amaral, Anna Bedbrook, Patrizia Bonadonna, Luisa Brussino, G. Walter Canonica, João Coutinho‐Almeida, Álvaro A. Cruz, Wienczyslawa Czarlewski, Mark Dykewicz, Mattia Giovannini, Bilun Gemicioglu, Juan Carlos Ivancevich, Ludger Klimek, Violeta Kvedariene, Desiree E. Larenas‐Linnemann, Manuel Marques‐Cruz, André Moreira, Marek Niedoszytko, Ana Margarida Pereira, Nikolaos G. Papadopoulos, Nhan Pham‐Thi, Frederico S. Regateiro, Sanna K. Toppila‐Salmi, Boleslaw Samolinski, Joaquin Sastre, Luís Taborda‐Barata, Tuuli Thomander, Ilgım Vardaloğlu Koyuncu, Arunas Valiulis, Leticia de las Vecillas, Maria Teresa Ventura, Jolanta Walusiak‐Skorupa, Yi‐Kui Xiang, Oliver Pfaar, João A. Fonseca, Torsten Zuberbier, Holger J. Schünemann, Danilo di Bona, Jean Bousquet   +45 more
wiley   +1 more source

CT‐P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study

Allergy, Volume 80, Issue 8, Page 2167-2177, August 2025.
This study investigated the therapeutic equivalence of CT‐P39 (an omalizumab biosimilar) and EU‐approved reference omalizumab (ref‐OMA) in patients with chronic spontaneous urticaria. Therapeutic equivalence between CT‐P39 and ref‑OMA (300 mg) was demonstrated by the primary endpoint – confidence intervals of the treatment difference in mean change ...
Sarbjit S. Saini, Marcus Maurer, Yevgeniya Dytyatkovska, Ewa Springer, Maria Ratkova, Borislava Krusheva, Chun Wook Park, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Jieun Ka, Jongho Kim, Clive Grattan   +16 more
wiley   +1 more source

Development of a green synchronous spectrofluorimetric technique for simultaneous determination of Montelukast sodium and Bilastine in pharmaceutical formulations

BMC Chemistry
For the treatment of rhinitis and asthma, a combination of Montelukast sodium and Bilastine has just been approved. Based on the first derivative of synchronous fluorescence, the current work developed a green, highly accurate, sensitive, and selective ...
Sayed M. Derayea, Khalid M. Badr El-Din, Ahmed S. Ahmed, Ahmed A. Khorshed, Mohamed Oraby   +4 more
doaj   +1 more source

Sleep Disturbance and Chronic Urticaria: A Narrative Review of Its Relationship, Treatment and Evolving Literature

Health Science Reports, Volume 8, Issue 5, May 2025.
ABSTRACT Background and Aims Chronic Spontaneous Urticaria is characterized by the sudden onset of itchy wheals and angioedema and is primarily driven by mast cells. It can have a significant impact on the Quality of Life (QoL) of an individual. While the role of mast cells in urticaria is extensively described, the link between sleep disorders and ...
Asad Ullah Wasim, Sri Anugna Miriyala, Raymond Haward, Zeinab Hammoud, Pratik Agarwal, Nirja Kaka, Neil Patel, Yashendra Sethi, Poonam Gupta   +8 more
wiley   +1 more source

The Response of Patients' Immune System After Facial Mesotherapy

Journal of Cosmetic Dermatology, Volume 24, Issue 2, February 2025.
ABSTRACT Background Facial mesotherapy is a minimally invasive cosmetic procedure involving the injection of active substances into the dermis and subcutaneous tissue. Although generally considered safe, complications such as granulomatous inflammation can arise due to improper techniques or unregulated products.
Olga Bobowska‐Guglas, Michał Chalcarz, Beniamin Oskar Grabarek, Tomasz Sirek, Jakub Żurawski   +4 more
wiley   +1 more source

Bilastine Based Drugs as SARS-CoV-2 Protease Inhibitors: Molecular Docking, Dynamics, and ADMET Related Studies

Orbital: The Electronic Journal of Chemistry, 2022
Bilastine drugs, structurally piperidine-1-carboxylate and sulfonyloxyethyl carboxylate derivatives, have significantly been employed as the medication of second-generation antihistamine drugs, and are used for the treatment of allergic ...
Ajoy Kumer, Unesco Chakma, Mohammed M. Matin   +2 more
doaj  

The new preservative-free ophthalmic formulation of bilastine 0.6% preserves the ocular surface epithelial integrity in a comparative in vitro study

Scientific Reports
Allergic conjunctivitis (AC) is the most common form of allergic eye disease and an increasingly prevalent condition. Topical eye drop treatments are the usual approach for managing AC, although their impact on the ocular surface is not frequently ...
Eider Arana, Ana Gonzalo, Noelia Andollo, Felipe Goñi-de-Cerio, Paloma Gómez-Fernández, Clarisa Salado, Gonzalo Hernández, Tatiana Suárez-Cortés   +7 more
doaj   +1 more source

Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial

Trials, 2020
Background Chronic spontaneous urticaria (CSU) is characterized by the spontaneous appearance of wheals, angioedema, or both for > 6 weeks. Continuous treatment with H1-antihistamines is used as a first-line treatment for CSU.
Atsushi Fukunaga, Yoshiko Oda, Ken Washio, Takashi Omori, Yasumasa Kakei, Michihiro Hide, Chikako Nishigori   +6 more
doaj   +1 more source

Bilastine association with lower risk of adverse events. A systematic review and meta-­analysis of randomized clinical trials.

, 2018
Preprint of the bilastine meta-analysis paper.
Tomasz Adamusiak (279075)
core   +1 more source

Ocular Biodistribution of Once-Daily 0.6% Bilastine Eye Drops Reveals Highest Levels in Conjunctiva Up to 24 h Postadministration

, 2022
PURPOSE: Bilastine is a second-generation antihistamine that has been shown to be effective for treatment of allergic conjunctivitis. The objective of this study was to evaluate the pharmacokinetics (PKs) and biodistribution of 0.6% bilastine ...
Gonzalo, Ana, Ganza, Álvaro, Zazpe, Arturo, Torrens, Inés, Hernández, Gonzalo   +4 more
core   +1 more source